| Timothy L Pansegrau, MD | |
|
222 N 7th St, Bismarck, ND 58501-4436 | |
| (701) 323-6000 | |
| (701) 323-5709 |
| Full Name | Timothy L Pansegrau |
|---|---|
| Gender | Male |
| Speciality | Cardiac Surgery |
| Experience | 35 Years |
| Location | 222 N 7th St, Bismarck, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871605279 | NPI | - | NPPES |
| 12951 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 9627 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Home Care | Mandan, ND | Home health agency |
| Sanford Medical Center Bismarck | Bismarck, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Bismarck | 9739098575 | 448 |
News Archive
Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas.
Clinical experience with the FDA cleared Axxent® Electronic Brachytherapy, eBx(TM), System from Xoft shows promise for the multi-disciplinary use of the isotope-free cancer treatment platform to deliver intraoperative radiation therapy (IORT). Xoft will showcase a variety of investigational IORT oncology applications at the American College of Surgeons 95th Annual Clinical Congress here in Chicago, October 11-15, 2009.
NPR's "Shots" blog reports on an update about the polio situation in Nigeria, published Thursday in the CDC's latest issue of Morbidity and Mortality Weekly Report (MMWR), writing, "Despite beefed-up efforts to vaccinate kids and a flood of new resources, ... there have been twice as many polio cases as last year, and a few communities, where kids chronically miss vaccines, are serving as 'sanctuaries' for the poliovirus, giving it a place to replicate and survive."
Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).
› Verified 4 days ago
| Entity Name | Sanford Bismarck |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811941172 PECOS PAC ID: 9739098575 Enrollment ID: O20031105000403 |
News Archive
Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas.
Clinical experience with the FDA cleared Axxent® Electronic Brachytherapy, eBx(TM), System from Xoft shows promise for the multi-disciplinary use of the isotope-free cancer treatment platform to deliver intraoperative radiation therapy (IORT). Xoft will showcase a variety of investigational IORT oncology applications at the American College of Surgeons 95th Annual Clinical Congress here in Chicago, October 11-15, 2009.
NPR's "Shots" blog reports on an update about the polio situation in Nigeria, published Thursday in the CDC's latest issue of Morbidity and Mortality Weekly Report (MMWR), writing, "Despite beefed-up efforts to vaccinate kids and a flood of new resources, ... there have been twice as many polio cases as last year, and a few communities, where kids chronically miss vaccines, are serving as 'sanctuaries' for the poliovirus, giving it a place to replicate and survive."
Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy L Pansegrau, MD Po Box 5501, Bismarck, ND 58506-5501 Ph: (701) 323-6000 | Timothy L Pansegrau, MD 222 N 7th St, Bismarck, ND 58501-4436 Ph: (701) 323-6000 |
News Archive
Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas.
Clinical experience with the FDA cleared Axxent® Electronic Brachytherapy, eBx(TM), System from Xoft shows promise for the multi-disciplinary use of the isotope-free cancer treatment platform to deliver intraoperative radiation therapy (IORT). Xoft will showcase a variety of investigational IORT oncology applications at the American College of Surgeons 95th Annual Clinical Congress here in Chicago, October 11-15, 2009.
NPR's "Shots" blog reports on an update about the polio situation in Nigeria, published Thursday in the CDC's latest issue of Morbidity and Mortality Weekly Report (MMWR), writing, "Despite beefed-up efforts to vaccinate kids and a flood of new resources, ... there have been twice as many polio cases as last year, and a few communities, where kids chronically miss vaccines, are serving as 'sanctuaries' for the poliovirus, giving it a place to replicate and survive."
Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).
› Verified 4 days ago
Dr. Ling Sing Chow, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Nicholas C Mahr, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 310 N 10th Street, Bismarck, ND 58501 Phone: 701-530-7500 Fax: 701-530-7484 | |
Dr. Maria Susana Castejon Welchez, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 | |
Dr. Sharmaine Habib, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 300 N 7th St, Bismarck, ND 58501 Phone: 701-323-8121 | |
Agnieszka Olga Solberg, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Amy Marie Kaminski, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 900 E Broadway Ave, Bismarck, ND 58501 Phone: 701-530-7000 | |
Ivaldo A Lunardi, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-6000 Fax: 701-323-5709 |